Share Price and Basic Stock Data
Last Updated: October 28, 2025, 7:00 pm
| PEG Ratio | 1.22 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
RPG Life Sciences Ltd operates in the pharmaceuticals industry, focusing on the development and manufacturing of medicines. The company’s stock price stood at ₹2,390 with a market capitalization of ₹3,953 Cr. Over the past fiscal years, RPG Life Sciences has shown a consistent upward trend in revenue, with reported sales of ₹513 Cr in FY 2023, increasing to ₹582 Cr in FY 2024, and further rising to ₹653 Cr in FY 2025. The trailing twelve months (TTM) revenue reached ₹657 Cr, indicating robust demand for its products. Quarterly sales have also demonstrated growth, with the latest quarter (June 2025) reporting ₹169 Cr, up from ₹165 Cr in the previous quarter. This consistent revenue growth reflects effective market strategies and a strong product portfolio, positioning the company favorably within the competitive landscape of the Indian pharmaceutical sector.
Profitability and Efficiency Metrics
RPG Life Sciences has reported impressive profitability metrics, with a net profit of ₹183 Cr for FY 2025, showcasing an increase from ₹68 Cr in FY 2023. The company’s operating profit margin (OPM) stood at 25% for FY 2025, up from 20% in FY 2023, indicating improved operational efficiency. The return on equity (ROE) recorded at 25.5% and return on capital employed (ROCE) at 32.8% further emphasize its strong profitability. The interest coverage ratio (ICR) is notably high at 277.95x, reflecting the company’s ability to comfortably meet its interest obligations, despite having no borrowings. However, the cash conversion cycle (CCC) of 72 days suggests room for improvement in working capital management, particularly in reducing inventory and debtor days, which are relatively high compared to industry norms.
Balance Sheet Strength and Financial Ratios
The balance sheet of RPG Life Sciences is robust, with total assets reported at ₹658 Cr and total liabilities at ₹127 Cr, indicating a healthy asset-to-liability ratio. The company has maintained zero borrowings, showcasing a strong capital structure with no financial leverage. Reserves have increased significantly to ₹517 Cr in FY 2025 from ₹294 Cr in FY 2023. The price-to-book value (P/BV) ratio is reported at 7.10x, which is high compared to typical sector ranges, signaling a strong market valuation but potentially higher risk for new investors. The current ratio is a solid 3.88, indicating good liquidity, while the quick ratio of 3.11 further emphasizes the company’s ability to cover short-term liabilities. Overall, RPG Life Sciences demonstrates a strong financial position with significant reserves and no debt burden.
Shareholding Pattern and Investor Confidence
RPG Life Sciences has a diverse shareholding structure, with promoters holding 72.95% of the equity as of March 2025. Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) have increased their stakes slightly, standing at 1.35% and 6.49%, respectively, indicating a growing interest from institutional investors. The public shareholding accounts for 19.22%, reflecting a considerable retail investor base. The total number of shareholders rose to 25,832, suggesting increasing investor confidence in the company’s future prospects. However, the low FII participation might indicate a cautious approach from foreign investors, possibly due to the high P/BV ratio and the competitive nature of the pharmaceutical sector. The stability in promoter holdings could provide reassurance to investors regarding the company’s governance and strategic direction.
Outlook, Risks, and Final Insight
RPG Life Sciences is well-positioned for future growth, driven by its strong financial performance and operational efficiencies. However, risks remain, including potential regulatory challenges in the pharmaceutical industry and market competition that could pressure margins. The high P/BV ratio may deter some investors, especially in a volatile market. Additionally, the company’s reliance on domestic sales could expose it to regional economic fluctuations. A potential strategy for RPG Life Sciences could involve diversifying its product portfolio or expanding into international markets to mitigate these risks. Maintaining operational efficiency and managing working capital effectively will be crucial for sustaining profitability. Given these factors, RPG Life Sciences presents a compelling investment opportunity, provided it can navigate the inherent challenges of the pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of RPG Life Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 114 | 247/84.3 | 32.8 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.80 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,983 Cr. | 460 | 479/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.2 Cr. | 22.0 | 29.1/17.0 | 33.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,766.58 Cr | 1,179.77 | 50.40 | 194.36 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 129 | 135 | 131 | 118 | 148 | 154 | 154 | 127 | 165 | 172 | 173 | 143 | 169 |
| Expenses | 101 | 105 | 101 | 103 | 116 | 116 | 116 | 106 | 126 | 126 | 124 | 118 | 133 |
| Operating Profit | 28 | 30 | 29 | 16 | 32 | 37 | 38 | 21 | 39 | 46 | 49 | 25 | 35 |
| OPM % | 22% | 22% | 22% | 13% | 22% | 24% | 25% | 16% | 24% | 27% | 28% | 18% | 21% |
| Other Income | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | -25 | 3 | 115 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 25 | 27 | 26 | 14 | 30 | 35 | 36 | 18 | 36 | 15 | 47 | 135 | 35 |
| Tax % | 28% | 26% | 26% | 25% | 26% | 26% | 26% | 25% | 26% | 72% | 26% | 13% | 26% |
| Net Profit | 18 | 20 | 19 | 10 | 22 | 26 | 26 | 13 | 27 | 4 | 35 | 117 | 26 |
| EPS in Rs | 11.01 | 12.07 | 11.55 | 6.26 | 13.36 | 15.64 | 16.00 | 8.01 | 16.18 | 2.54 | 21.12 | 70.95 | 15.90 |
Last Updated: August 1, 2025, 1:05 pm
Below is a detailed analysis of the quarterly data for RPG Life Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 169.00 Cr.. The value appears strong and on an upward trend. It has increased from 143.00 Cr. (Mar 2025) to 169.00 Cr., marking an increase of 26.00 Cr..
- For Expenses, as of Jun 2025, the value is 133.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 118.00 Cr. (Mar 2025) to 133.00 Cr., marking an increase of 15.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 10.00 Cr..
- For OPM %, as of Jun 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Mar 2025) to 21.00%, marking an increase of 3.00%.
- For Other Income, as of Jun 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 115.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 110.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 135.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 100.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 13.00% (Mar 2025) to 26.00%, marking an increase of 13.00%.
- For Net Profit, as of Jun 2025, the value is 26.00 Cr.. The value appears to be declining and may need further review. It has decreased from 117.00 Cr. (Mar 2025) to 26.00 Cr., marking a decrease of 91.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 15.90. The value appears to be declining and may need further review. It has decreased from 70.95 (Mar 2025) to 15.90, marking a decrease of 55.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 2:10 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 236 | 242 | 279 | 294 | 344 | 330 | 376 | 389 | 440 | 513 | 582 | 653 | 657 |
| Expenses | 224 | 228 | 256 | 274 | 306 | 296 | 315 | 318 | 353 | 408 | 453 | 493 | 501 |
| Operating Profit | 12 | 14 | 23 | 20 | 38 | 34 | 60 | 71 | 87 | 104 | 129 | 161 | 156 |
| OPM % | 5% | 6% | 8% | 7% | 11% | 10% | 16% | 18% | 20% | 20% | 22% | 25% | 24% |
| Other Income | 66 | 1 | 1 | 18 | 1 | 1 | -5 | 1 | 3 | 4 | 7 | 95 | 98 |
| Interest | 3 | 3 | 2 | 4 | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 11 | 11 | 10 | 11 | 14 | 15 | 16 | 16 | 16 | 16 | 17 | 21 | 21 |
| Profit before tax | 65 | 1 | 12 | 23 | 20 | 15 | 36 | 54 | 73 | 92 | 118 | 233 | 232 |
| Tax % | 18% | 0% | 0% | 10% | 34% | 28% | 20% | 25% | 30% | 26% | 26% | 21% | |
| Net Profit | 53 | 1 | 12 | 21 | 13 | 11 | 29 | 40 | 51 | 68 | 88 | 183 | 183 |
| EPS in Rs | 32.29 | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 53.00 | 110.79 | 110.51 |
| Dividend Payout % | 6% | 132% | 23% | 22% | 30% | 37% | 23% | 30% | 31% | 29% | 30% | 22% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -98.11% | 1100.00% | 75.00% | -38.10% | -15.38% | 163.64% | 37.93% | 27.50% | 33.33% | 29.41% | 107.95% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1198.11% | -1025.00% | -113.10% | 22.71% | 179.02% | -125.71% | -10.43% | 5.83% | -3.92% | 78.54% |
RPG Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 63% |
| 5 Years: | 29% |
| 3 Years: | 31% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 46% |
| 3 Years: | 46% |
| 1 Year: | 6% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 24% |
| 3 Years: | 25% |
| Last Year: | 26% |
Last Updated: September 5, 2025, 1:10 pm
Balance Sheet
Last Updated: July 25, 2025, 2:27 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 113 | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 362 | 517 |
| Borrowings | 15 | 33 | 23 | 45 | 54 | 36 | 12 | 2 | 1 | 0 | 0 | 0 |
| Other Liabilities | 56 | 39 | 49 | 55 | 82 | 54 | 78 | 85 | 88 | 112 | 138 | 127 |
| Total Liabilities | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 |
| Fixed Assets | 106 | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 114 | 172 |
| CWIP | 1 | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 96 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 91 | 127 |
| Other Assets | 89 | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | 343 |
| Total Assets | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 |
Below is a detailed analysis of the balance sheet data for RPG Life Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
- For Reserves, as of Mar 2025, the value is 517.00 Cr.. The value appears strong and on an upward trend. It has increased from 362.00 Cr. (Mar 2024) to 517.00 Cr., marking an increase of 155.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 127.00 Cr.. The value appears to be improving (decreasing). It has decreased from 138.00 Cr. (Mar 2024) to 127.00 Cr., marking a decrease of 11.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 658.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 513.00 Cr. (Mar 2024) to 658.00 Cr., marking an increase of 145.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 172.00 Cr.. The value appears strong and on an upward trend. It has increased from 114.00 Cr. (Mar 2024) to 172.00 Cr., marking an increase of 58.00 Cr..
- For CWIP, as of Mar 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 96.00 Cr. (Mar 2024) to 16.00 Cr., marking a decrease of 80.00 Cr..
- For Investments, as of Mar 2025, the value is 127.00 Cr.. The value appears strong and on an upward trend. It has increased from 91.00 Cr. (Mar 2024) to 127.00 Cr., marking an increase of 36.00 Cr..
- For Other Assets, as of Mar 2025, the value is 343.00 Cr.. The value appears strong and on an upward trend. It has increased from 212.00 Cr. (Mar 2024) to 343.00 Cr., marking an increase of 131.00 Cr..
- For Total Assets, as of Mar 2025, the value is 658.00 Cr.. The value appears strong and on an upward trend. It has increased from 513.00 Cr. (Mar 2024) to 658.00 Cr., marking an increase of 145.00 Cr..
Notably, the Reserves (517.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -3.00 | -19.00 | 0.00 | -25.00 | -16.00 | -2.00 | 48.00 | 69.00 | 86.00 | 104.00 | 129.00 | 161.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 61 | 48 | 49 | 72 | 43 | 62 | 54 | 27 | 27 | 31 | 48 |
| Inventory Days | 180 | 149 | 156 | 163 | 171 | 136 | 133 | 162 | 214 | 203 | 200 | 159 |
| Days Payable | 176 | 109 | 135 | 102 | 165 | 83 | 127 | 132 | 117 | 138 | 140 | 135 |
| Cash Conversion Cycle | 60 | 101 | 70 | 110 | 78 | 96 | 68 | 84 | 124 | 91 | 90 | 72 |
| Working Capital Days | 30 | 27 | 26 | 20 | 22 | 20 | 41 | 52 | 47 | 33 | 25 | 45 |
| ROCE % | 2% | 2% | 9% | 10% | 13% | 10% | 23% | 27% | 31% | 33% | 35% | 33% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Mirae Asset Multicap Fund | 165,269 | 1.18 | 22.98 | 165,269 | 2025-04-22 16:51:54 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 47 | 0.07 | 0.01 | 47 | 2025-04-22 17:25:21 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 |
| Basic EPS (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 |
| Diluted EPS (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 |
| Cash EPS (Rs.) | 123.76 | 63.33 | 50.27 | 40.60 | 34.15 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 320.80 | 226.67 | 186.00 | 154.66 | 130.88 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 320.80 | 226.67 | 186.00 | 154.66 | 130.88 |
| Dividend / Share (Rs.) | 24.00 | 16.00 | 12.00 | 9.60 | 7.20 |
| Revenue From Operations / Share (Rs.) | 395.12 | 351.96 | 310.09 | 266.16 | 235.31 |
| PBDIT / Share (Rs.) | 104.20 | 81.85 | 65.00 | 54.03 | 42.84 |
| PBIT / Share (Rs.) | 91.25 | 71.53 | 55.62 | 44.56 | 32.88 |
| PBT / Share (Rs.) | 140.82 | 71.26 | 55.44 | 44.24 | 32.40 |
| Net Profit / Share (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 |
| PBDIT Margin (%) | 26.37 | 23.25 | 20.96 | 20.29 | 18.20 |
| PBIT Margin (%) | 23.09 | 20.32 | 17.93 | 16.74 | 13.97 |
| PBT Margin (%) | 35.63 | 20.24 | 17.87 | 16.62 | 13.76 |
| Net Profit Margin (%) | 28.04 | 15.06 | 13.19 | 11.69 | 10.27 |
| Return on Networth / Equity (%) | 34.53 | 23.38 | 21.98 | 20.12 | 18.48 |
| Return on Capital Employeed (%) | 28.04 | 30.97 | 29.05 | 27.86 | 24.30 |
| Return On Assets (%) | 27.85 | 17.09 | 16.12 | 14.93 | 13.18 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset Turnover Ratio (%) | 1.12 | 1.25 | 1.34 | 1.36 | 1.37 |
| Current Ratio (X) | 3.88 | 2.28 | 2.57 | 2.58 | 2.21 |
| Quick Ratio (X) | 3.11 | 1.50 | 1.64 | 1.55 | 1.47 |
| Inventory Turnover Ratio (X) | 1.14 | 1.23 | 0.96 | 1.25 | 1.63 |
| Dividend Payout Ratio (NP) (%) | 14.44 | 22.64 | 23.47 | 23.13 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 12.92 | 18.95 | 19.10 | 17.73 | 0.00 |
| Earning Retention Ratio (%) | 85.56 | 77.36 | 76.53 | 76.87 | 0.00 |
| Cash Earning Retention Ratio (%) | 87.08 | 81.05 | 80.90 | 82.27 | 0.00 |
| Interest Coverage Ratio (X) | 277.95 | 300.80 | 346.74 | 171.83 | 89.67 |
| Interest Coverage Ratio (Post Tax) (X) | 163.32 | 195.80 | 219.19 | 100.00 | 51.63 |
| Enterprise Value (Cr.) | 3626.89 | 2494.10 | 1093.81 | 855.55 | 600.68 |
| EV / Net Operating Revenue (X) | 5.55 | 4.29 | 2.13 | 1.94 | 1.54 |
| EV / EBITDA (X) | 21.05 | 18.43 | 10.18 | 9.58 | 8.48 |
| MarketCap / Net Operating Revenue (X) | 5.76 | 4.35 | 2.24 | 2.10 | 1.65 |
| Retention Ratios (%) | 85.55 | 77.35 | 76.52 | 76.86 | 0.00 |
| Price / BV (X) | 7.10 | 6.75 | 3.74 | 3.62 | 2.96 |
| Price / Net Operating Revenue (X) | 5.76 | 4.35 | 2.24 | 2.10 | 1.65 |
| EarningsYield | 0.04 | 0.03 | 0.05 | 0.05 | 0.06 |
After reviewing the key financial ratios for RPG Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 8.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 8.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 123.76. This value is within the healthy range. It has increased from 63.33 (Mar 24) to 123.76, marking an increase of 60.43.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 320.80. It has increased from 226.67 (Mar 24) to 320.80, marking an increase of 94.13.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 320.80. It has increased from 226.67 (Mar 24) to 320.80, marking an increase of 94.13.
- For Dividend / Share (Rs.), as of Mar 25, the value is 24.00. This value exceeds the healthy maximum of 3. It has increased from 16.00 (Mar 24) to 24.00, marking an increase of 8.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 395.12. It has increased from 351.96 (Mar 24) to 395.12, marking an increase of 43.16.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 104.20. This value is within the healthy range. It has increased from 81.85 (Mar 24) to 104.20, marking an increase of 22.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is 91.25. This value is within the healthy range. It has increased from 71.53 (Mar 24) to 91.25, marking an increase of 19.72.
- For PBT / Share (Rs.), as of Mar 25, the value is 140.82. This value is within the healthy range. It has increased from 71.26 (Mar 24) to 140.82, marking an increase of 69.56.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
- For PBDIT Margin (%), as of Mar 25, the value is 26.37. This value is within the healthy range. It has increased from 23.25 (Mar 24) to 26.37, marking an increase of 3.12.
- For PBIT Margin (%), as of Mar 25, the value is 23.09. This value exceeds the healthy maximum of 20. It has increased from 20.32 (Mar 24) to 23.09, marking an increase of 2.77.
- For PBT Margin (%), as of Mar 25, the value is 35.63. This value is within the healthy range. It has increased from 20.24 (Mar 24) to 35.63, marking an increase of 15.39.
- For Net Profit Margin (%), as of Mar 25, the value is 28.04. This value exceeds the healthy maximum of 10. It has increased from 15.06 (Mar 24) to 28.04, marking an increase of 12.98.
- For Return on Networth / Equity (%), as of Mar 25, the value is 34.53. This value is within the healthy range. It has increased from 23.38 (Mar 24) to 34.53, marking an increase of 11.15.
- For Return on Capital Employeed (%), as of Mar 25, the value is 28.04. This value is within the healthy range. It has decreased from 30.97 (Mar 24) to 28.04, marking a decrease of 2.93.
- For Return On Assets (%), as of Mar 25, the value is 27.85. This value is within the healthy range. It has increased from 17.09 (Mar 24) to 27.85, marking an increase of 10.76.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.12. It has decreased from 1.25 (Mar 24) to 1.12, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has increased from 2.28 (Mar 24) to 3.88, marking an increase of 1.60.
- For Quick Ratio (X), as of Mar 25, the value is 3.11. This value exceeds the healthy maximum of 2. It has increased from 1.50 (Mar 24) to 3.11, marking an increase of 1.61.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 4. It has decreased from 1.23 (Mar 24) to 1.14, marking a decrease of 0.09.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 14.44. This value is below the healthy minimum of 20. It has decreased from 22.64 (Mar 24) to 14.44, marking a decrease of 8.20.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 12.92. This value is below the healthy minimum of 20. It has decreased from 18.95 (Mar 24) to 12.92, marking a decrease of 6.03.
- For Earning Retention Ratio (%), as of Mar 25, the value is 85.56. This value exceeds the healthy maximum of 70. It has increased from 77.36 (Mar 24) to 85.56, marking an increase of 8.20.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 87.08. This value exceeds the healthy maximum of 70. It has increased from 81.05 (Mar 24) to 87.08, marking an increase of 6.03.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 277.95. This value is within the healthy range. It has decreased from 300.80 (Mar 24) to 277.95, marking a decrease of 22.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 163.32. This value is within the healthy range. It has decreased from 195.80 (Mar 24) to 163.32, marking a decrease of 32.48.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,626.89. It has increased from 2,494.10 (Mar 24) to 3,626.89, marking an increase of 1,132.79.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.55. This value exceeds the healthy maximum of 3. It has increased from 4.29 (Mar 24) to 5.55, marking an increase of 1.26.
- For EV / EBITDA (X), as of Mar 25, the value is 21.05. This value exceeds the healthy maximum of 15. It has increased from 18.43 (Mar 24) to 21.05, marking an increase of 2.62.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.76. This value exceeds the healthy maximum of 3. It has increased from 4.35 (Mar 24) to 5.76, marking an increase of 1.41.
- For Retention Ratios (%), as of Mar 25, the value is 85.55. This value exceeds the healthy maximum of 70. It has increased from 77.35 (Mar 24) to 85.55, marking an increase of 8.20.
- For Price / BV (X), as of Mar 25, the value is 7.10. This value exceeds the healthy maximum of 3. It has increased from 6.75 (Mar 24) to 7.10, marking an increase of 0.35.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.76. This value exceeds the healthy maximum of 3. It has increased from 4.35 (Mar 24) to 5.76, marking an increase of 1.41.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in RPG Life Sciences Ltd:
- Net Profit Margin: 28.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 28.04% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 34.53% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 163.32
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.11
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 35.3 (Industry average Stock P/E: 50.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 28.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | RPG House, Mumbai Maharashtra 400030 | investorservices@rpgls.com http://www.rpglifesciences.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Harsh V Goenka | Chairman |
| Mr. Ashok Nair | Managing Director |
| Mr. Rajat Bhargava | Non Executive Director |
| Mr. Yugal Sikri | Non Executive Director |
| Ms. Vasundhara Patni | Non Executive Director |
| Mr. Manoj K Maheshwari | Independent Director |
| Ms. Zahabiya Khorakiwala | Independent Director |
| Mr. Bhaskar Iyer | Independent Director |
| Mr. Sachin Nandgaonkar | Independent Director |
| Ms. Radhika Gupta | Independent Director |
| Mr. Hiten Kotak | Independent Director |
| Mr. Anil Matai | Independent Director |
FAQ
What is the intrinsic value of RPG Life Sciences Ltd?
RPG Life Sciences Ltd's intrinsic value (as of 28 October 2025) is 2432.67 which is 2.30% higher the current market price of 2,378.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 3,936 Cr. market cap, FY2025-2026 high/low of 2,776/1,772, reserves of ₹517 Cr, and liabilities of 658 Cr.
What is the Market Cap of RPG Life Sciences Ltd?
The Market Cap of RPG Life Sciences Ltd is 3,936 Cr..
What is the current Stock Price of RPG Life Sciences Ltd as on 28 October 2025?
The current stock price of RPG Life Sciences Ltd as on 28 October 2025 is 2,378.
What is the High / Low of RPG Life Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of RPG Life Sciences Ltd stocks is 2,776/1,772.
What is the Stock P/E of RPG Life Sciences Ltd?
The Stock P/E of RPG Life Sciences Ltd is 35.3.
What is the Book Value of RPG Life Sciences Ltd?
The Book Value of RPG Life Sciences Ltd is 335.
What is the Dividend Yield of RPG Life Sciences Ltd?
The Dividend Yield of RPG Life Sciences Ltd is 0.84 %.
What is the ROCE of RPG Life Sciences Ltd?
The ROCE of RPG Life Sciences Ltd is 32.8 %.
What is the ROE of RPG Life Sciences Ltd?
The ROE of RPG Life Sciences Ltd is 25.5 %.
What is the Face Value of RPG Life Sciences Ltd?
The Face Value of RPG Life Sciences Ltd is 8.00.